Advent acquires majority stake in NZCR Group for $1 billion
Global private equity investor Advent has agreed to buy a majority stake in clinical trials and medical research organisation NZCR Group.
Advent, a private equity investor, will acquire a majority stake in New Zealand Clinical Research Group, a clinical trials and medical research organisation operating in New Zealand and Australia. The deal is valued at approximately $1 billion and is subject to customary regulatory approvals. The transaction is expected to close in the fourth quarter of 2026.
Covered byBusinessDeskNot covered byRNZStuffNZ Herald1NewsNewstalk ZBOtago Daily TimesNewsroomThe Spinoffinterest.co.nz
Coverage across the news outlets we track, as at publication.
What outlets are saying
BusinessDesk
Advent acquires majority stake in NZCR Group
Advent, a global private equity investor, has announced a majority investment in New Zealand Clinical Research Group (NZCR Group), a clinical trials and medical research organisation in New Zealand and Australia. The terms of the transaction were not disclosed.
BusinessDesk
Advent to buy majority stake in NZCR in deal valued at $1b
Private equity investor Advent will acquire a majority stake in clinical trials and medical research organisation New Zealand Clinical Research Group (NZCR Group) in a deal understood to value the company at about $1 billion. The transaction is subject to…